Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK3 A573V and JAK3 M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway.

Journal for immunotherapy of cancer - 8 Apr 2025

Lou Ning, Yang Mengwei, Xie Zucheng, Gao Ruyun, Zhang Lei, Tang Le, Yao Jiarui, Han Xiaohong, Shi Yuankai

Abstract excerpt

BACKGROUND: Clinical evidence has established anti-PD-1 antibody as a transformative treatment modality for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL), yet reveals a therapeutic plateau with drug resistance observed in 60% of r/r PTCL. The biological determinants underlying this resistance-particularly the complex interplay between tumor-intrinsic characteristics (including tumor mutation burden...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Janus Kinase 3

Share to Lymphoma, T-Cell, Peripheral

Share to Signal Transduction

Share to STAT3 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 40199606
DOI: 10.1136/jitc-2024-010783
PMCID: PMC11979606

Genes

JAK3
STAT3
F3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK3 A573V and JAK3 M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway.PMID 40199606Read ↗

Peripheral T cell lymphomas: from the bench to the clinic.Semantic proximity Read ↗

Single-cell sequencing uncovers clonal dynamics profiles and therapeutic resistance biomarkers in relapsed and refractory peripheral T-cell lymphomaSemantic proximity Read ↗

FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T cell lymphoma, not otherwise specifiedSemantic proximity Read ↗

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilitiesSemantic proximity Read ↗

Emerging strategies in peripheral T-cell lymphoma.Semantic proximity Read ↗

New insights into the biology of T-cell lymphomasSemantic proximity Read ↗

Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesisSemantic proximity Read ↗

Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profilingSemantic proximity Read ↗

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphomaSemantic proximity Read ↗

Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targetsSemantic proximity Read ↗

Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.Semantic proximity Read ↗

Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specifiedSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.